During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
Atrial fibrillation (AF) and chronic heart failure (CHF) are two major and even growing cardiovascular conditions that often coexist. However, few data are available to guide treatment of AF in ...
Neurosurgery, in combination with other medical and rehabilitation treatments, is instrumental in improving outcomes for ...
If the ECG machine readings indicate that a patient has AF, their GP is informed, and they can discuss treatment options ... people who are at risk of atrial fibrillation and who may benefit ...
Treatment options for patients with esophageal squamous cell carcinoma (ESCC) often result in poor prognosis and declining health-related quality of life. Screening FDA-approved drugs for cancer ...
AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
In an ongoing trial, a ground-breaking tool scours GP records for “red flags” which could indicate whether a patient was at risk of developing atrial fibrillation (AF). John Pengelly ...
Report on how AI is driving market transformation - The global heparin market  size is estimated to grow by USD 3.34 billion from 2024-2028, according to Technavio. The market is estimated to grow at ...
Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.
The commercialisation of junk food, increase in inactive lifestyles with prolonged sitting, and high stress environments, ...